nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—lung cancer—esophageal cancer	0.586	1	CtDrD
Topotecan—ABCB1—esophageal cancer	0.172	1	CbGaD
Topotecan—ABCG2—Carboplatin—esophageal cancer	0.053	0.343	CbGbCtD
Topotecan—ABCG2—Cisplatin—esophageal cancer	0.0453	0.293	CbGbCtD
Topotecan—ABCG2—Methotrexate—esophageal cancer	0.0294	0.19	CbGbCtD
Topotecan—ABCB1—Cisplatin—esophageal cancer	0.0163	0.106	CbGbCtD
Topotecan—ABCB1—Methotrexate—esophageal cancer	0.0106	0.0686	CbGbCtD
Topotecan—Hepatic pain—Capecitabine—esophageal cancer	0.00458	0.0862	CcSEcCtD
Topotecan—Metastatic neoplasm—Cisplatin—esophageal cancer	0.0027	0.0508	CcSEcCtD
Topotecan—Extravasation—Carboplatin—esophageal cancer	0.00202	0.0381	CcSEcCtD
Topotecan—Irinotecan—ABCC2—esophageal cancer	0.00183	0.731	CrCbGaD
Topotecan—Acute leukaemia—Cisplatin—esophageal cancer	0.00181	0.0341	CcSEcCtD
Topotecan—Myelosuppression—Cisplatin—esophageal cancer	0.0011	0.0208	CcSEcCtD
Topotecan—Febrile neutropenia—Cisplatin—esophageal cancer	0.000861	0.0162	CcSEcCtD
Topotecan—Paresis—Methotrexate—esophageal cancer	0.000779	0.0147	CcSEcCtD
Topotecan—Mucosal inflammation—Capecitabine—esophageal cancer	0.00069	0.013	CcSEcCtD
Topotecan—Irinotecan—ABCB1—esophageal cancer	0.000675	0.269	CrCbGaD
Topotecan—Febrile neutropenia—Capecitabine—esophageal cancer	0.000635	0.0119	CcSEcCtD
Topotecan—Infection—Carboplatin—esophageal cancer	0.000626	0.0118	CcSEcCtD
Topotecan—Extravasation—Cisplatin—esophageal cancer	0.000594	0.0112	CcSEcCtD
Topotecan—Intestinal obstruction—Capecitabine—esophageal cancer	0.00056	0.0105	CcSEcCtD
Topotecan—Neuralgia—Capecitabine—esophageal cancer	0.00055	0.0103	CcSEcCtD
Topotecan—Pain—Carboplatin—esophageal cancer	0.000539	0.0101	CcSEcCtD
Topotecan—Mucosal inflammation—Methotrexate—esophageal cancer	0.000514	0.00966	CcSEcCtD
Topotecan—TOP1MT—lung—esophageal cancer	0.000509	0.168	CbGeAlD
Topotecan—Rash erythematous—Capecitabine—esophageal cancer	0.000499	0.00938	CcSEcCtD
Topotecan—Pleural effusion—Capecitabine—esophageal cancer	0.000499	0.00938	CcSEcCtD
Topotecan—Body temperature increased—Carboplatin—esophageal cancer	0.000498	0.00937	CcSEcCtD
Topotecan—Neuropathy—Cisplatin—esophageal cancer	0.000486	0.00915	CcSEcCtD
Topotecan—Febrile neutropenia—Methotrexate—esophageal cancer	0.000473	0.00889	CcSEcCtD
Topotecan—Rigors—Capecitabine—esophageal cancer	0.000468	0.0088	CcSEcCtD
Topotecan—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00042	0.0079	CcSEcCtD
Topotecan—TOP1—bronchus—esophageal cancer	0.000416	0.138	CbGeAlD
Topotecan—TOP1—smooth muscle tissue—esophageal cancer	0.000407	0.135	CbGeAlD
Topotecan—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000404	0.00759	CcSEcCtD
Topotecan—Interstitial lung disease—Methotrexate—esophageal cancer	0.000402	0.00756	CcSEcCtD
Topotecan—Lung disorder—Methotrexate—esophageal cancer	0.000402	0.00756	CcSEcCtD
Topotecan—Bone pain—Capecitabine—esophageal cancer	0.000399	0.0075	CcSEcCtD
Topotecan—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000389	0.00731	CcSEcCtD
Topotecan—Pulmonary embolism—Capecitabine—esophageal cancer	0.000382	0.00718	CcSEcCtD
Topotecan—TOP1—trachea—esophageal cancer	0.000373	0.124	CbGeAlD
Topotecan—Pleural effusion—Methotrexate—esophageal cancer	0.000371	0.00698	CcSEcCtD
Topotecan—Colitis—Capecitabine—esophageal cancer	0.000367	0.0069	CcSEcCtD
Topotecan—Neuropathy—Capecitabine—esophageal cancer	0.000359	0.00674	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000351	0.0122	CbGpPWpGaD
Topotecan—TOP1—Circadian rythm related genes—GHRL—esophageal cancer	0.000349	0.0121	CbGpPWpGaD
Topotecan—TOP1MT—lymph node—esophageal cancer	0.000348	0.115	CbGeAlD
Topotecan—Neoplasm—Capecitabine—esophageal cancer	0.000345	0.00649	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000339	0.00637	CcSEcCtD
Topotecan—Cramp muscle—Cisplatin—esophageal cancer	0.000339	0.00637	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000334	0.0116	CbGpPWpGaD
Topotecan—Sepsis—Capecitabine—esophageal cancer	0.000331	0.00623	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.000328	0.0114	CbGpPWpGaD
Topotecan—Extravasation—Methotrexate—esophageal cancer	0.000326	0.00613	CcSEcCtD
Topotecan—Ear pain—Capecitabine—esophageal cancer	0.000325	0.00611	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.00032	0.0111	CbGpPWpGaD
Topotecan—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000313	0.00588	CcSEcCtD
Topotecan—Pancytopenia—Cisplatin—esophageal cancer	0.000309	0.00581	CcSEcCtD
Topotecan—Dermatitis bullous—Capecitabine—esophageal cancer	0.00029	0.00546	CcSEcCtD
Topotecan—Respiratory failure—Methotrexate—esophageal cancer	0.00029	0.00545	CcSEcCtD
Topotecan—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.000288	0.00999	CbGpPWpGaD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.000287	0.00996	CbGpPWpGaD
Topotecan—Pulmonary embolism—Methotrexate—esophageal cancer	0.000284	0.00535	CcSEcCtD
Topotecan—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000284	0.00534	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000283	0.00981	CbGpPWpGaD
Topotecan—Lethargy—Capecitabine—esophageal cancer	0.000283	0.00532	CcSEcCtD
Topotecan—Stomatitis—Cisplatin—esophageal cancer	0.000283	0.00531	CcSEcCtD
Topotecan—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000274	0.00516	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000274	0.0095	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000274	0.0095	CbGpPWpGaD
Topotecan—TOP1—lung—esophageal cancer	0.000268	0.0889	CbGeAlD
Topotecan—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.000265	0.00918	CbGpPWpGaD
Topotecan—Cardiac arrest—Capecitabine—esophageal cancer	0.000264	0.00496	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000261	0.00903	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000259	0.00899	CbGpPWpGaD
Topotecan—Neoplasm—Methotrexate—esophageal cancer	0.000257	0.00483	CcSEcCtD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000254	0.00882	CbGpPWpGaD
Topotecan—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00025	0.0047	CcSEcCtD
Topotecan—Sepsis—Methotrexate—esophageal cancer	0.000247	0.00464	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000245	0.0046	CcSEcCtD
Topotecan—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.000243	0.00842	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000237	0.00822	CbGpPWpGaD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000237	0.00822	CbGpPWpGaD
Topotecan—Immune system disorder—Cisplatin—esophageal cancer	0.000235	0.00442	CcSEcCtD
Topotecan—Mediastinal disorder—Cisplatin—esophageal cancer	0.000235	0.00441	CcSEcCtD
Topotecan—Alopecia—Cisplatin—esophageal cancer	0.00023	0.00432	CcSEcCtD
Topotecan—Pancytopenia—Capecitabine—esophageal cancer	0.000228	0.00428	CcSEcCtD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000227	0.00786	CbGpPWpGaD
Topotecan—Malnutrition—Cisplatin—esophageal cancer	0.000227	0.00426	CcSEcCtD
Topotecan—Neutropenia—Capecitabine—esophageal cancer	0.000224	0.00421	CcSEcCtD
Topotecan—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000222	0.00769	CbGpPWpGaD
Topotecan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00022	0.00762	CbGpPWpGaD
Topotecan—Weight increased—Capecitabine—esophageal cancer	0.000218	0.0041	CcSEcCtD
Topotecan—Muscle spasms—Cisplatin—esophageal cancer	0.000218	0.0041	CcSEcCtD
Topotecan—Pneumonia—Capecitabine—esophageal cancer	0.000215	0.00404	CcSEcCtD
Topotecan—Infestation—Capecitabine—esophageal cancer	0.000214	0.00402	CcSEcCtD
Topotecan—Infestation NOS—Capecitabine—esophageal cancer	0.000214	0.00402	CcSEcCtD
Topotecan—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000213	0.00401	CcSEcCtD
Topotecan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000211	0.00733	CbGpPWpGaD
Topotecan—Lethargy—Methotrexate—esophageal cancer	0.000211	0.00396	CcSEcCtD
Topotecan—Ill-defined disorder—Cisplatin—esophageal cancer	0.00021	0.00395	CcSEcCtD
Topotecan—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000209	0.00394	CcSEcCtD
Topotecan—Anaemia—Cisplatin—esophageal cancer	0.000209	0.00394	CcSEcCtD
Topotecan—Stomatitis—Capecitabine—esophageal cancer	0.000208	0.00392	CcSEcCtD
Topotecan—Malaise—Cisplatin—esophageal cancer	0.000204	0.00384	CcSEcCtD
Topotecan—Leukopenia—Cisplatin—esophageal cancer	0.000203	0.00381	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.000202	0.00701	CbGpPWpGaD
Topotecan—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000202	0.0038	CcSEcCtD
Topotecan—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.000202	0.007	CbGpPWpGaD
Topotecan—Epistaxis—Capecitabine—esophageal cancer	0.000202	0.00379	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—NOS2—esophageal cancer	0.000196	0.00679	CbGpPWpGaD
Topotecan—Myalgia—Cisplatin—esophageal cancer	0.000193	0.00363	CcSEcCtD
Topotecan—Haemoglobin—Capecitabine—esophageal cancer	0.000193	0.00363	CcSEcCtD
Topotecan—Rhinitis—Capecitabine—esophageal cancer	0.000192	0.00362	CcSEcCtD
Topotecan—Haemorrhage—Capecitabine—esophageal cancer	0.000192	0.00361	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000192	0.0036	CcSEcCtD
Topotecan—Hypoaesthesia—Capecitabine—esophageal cancer	0.000191	0.00359	CcSEcCtD
Topotecan—Discomfort—Cisplatin—esophageal cancer	0.000191	0.00358	CcSEcCtD
Topotecan—Pharyngitis—Capecitabine—esophageal cancer	0.00019	0.00358	CcSEcCtD
Topotecan—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00019	0.0066	CbGpPWpGaD
Topotecan—Anaphylactic shock—Cisplatin—esophageal cancer	0.000185	0.00348	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000184	0.00638	CbGpPWpGaD
Topotecan—Infection—Cisplatin—esophageal cancer	0.000184	0.00345	CcSEcCtD
Topotecan—TOP1—lymph node—esophageal cancer	0.000184	0.0608	CbGeAlD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000183	0.00635	CbGpPWpGaD
Topotecan—Nervous system disorder—Cisplatin—esophageal cancer	0.000181	0.00341	CcSEcCtD
Topotecan—Thrombocytopenia—Cisplatin—esophageal cancer	0.000181	0.0034	CcSEcCtD
Topotecan—Skin disorder—Cisplatin—esophageal cancer	0.00018	0.00338	CcSEcCtD
Topotecan—ABCG2—Iron uptake and transport—HMOX1—esophageal cancer	0.000179	0.00621	CbGpPWpGaD
Topotecan—Hyperhidrosis—Cisplatin—esophageal cancer	0.000179	0.00336	CcSEcCtD
Topotecan—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000177	0.00615	CbGpPWpGaD
Topotecan—Anorexia—Cisplatin—esophageal cancer	0.000176	0.00331	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000174	0.00604	CbGpPWpGaD
Topotecan—Angiopathy—Capecitabine—esophageal cancer	0.000174	0.00327	CcSEcCtD
Topotecan—Immune system disorder—Capecitabine—esophageal cancer	0.000173	0.00326	CcSEcCtD
Topotecan—Mediastinal disorder—Capecitabine—esophageal cancer	0.000173	0.00325	CcSEcCtD
Topotecan—Chills—Capecitabine—esophageal cancer	0.000172	0.00324	CcSEcCtD
Topotecan—Alopecia—Capecitabine—esophageal cancer	0.000169	0.00319	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—esophageal cancer	0.000169	0.00319	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000168	0.00317	CcSEcCtD
Topotecan—Malnutrition—Capecitabine—esophageal cancer	0.000167	0.00314	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—esophageal cancer	0.000167	0.00314	CcSEcCtD
Topotecan—Paraesthesia—Cisplatin—esophageal cancer	0.000166	0.00312	CcSEcCtD
Topotecan—Dyspnoea—Cisplatin—esophageal cancer	0.000165	0.0031	CcSEcCtD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—KDR—esophageal cancer	0.000162	0.00563	CbGpPWpGaD
Topotecan—Back pain—Capecitabine—esophageal cancer	0.000162	0.00304	CcSEcCtD
Topotecan—Decreased appetite—Cisplatin—esophageal cancer	0.000161	0.00302	CcSEcCtD
Topotecan—Muscle spasms—Capecitabine—esophageal cancer	0.000161	0.00302	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—esophageal cancer	0.00016	0.00301	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.00016	0.00554	CbGpPWpGaD
Topotecan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00016	0.003	CcSEcCtD
Topotecan—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.000159	0.00552	CbGpPWpGaD
Topotecan—Infestation NOS—Methotrexate—esophageal cancer	0.000159	0.00299	CcSEcCtD
Topotecan—Infestation—Methotrexate—esophageal cancer	0.000159	0.00299	CcSEcCtD
Topotecan—Pain—Cisplatin—esophageal cancer	0.000158	0.00297	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000158	0.00547	CbGpPWpGaD
Topotecan—Stomatitis—Methotrexate—esophageal cancer	0.000155	0.00292	CcSEcCtD
Topotecan—Ill-defined disorder—Capecitabine—esophageal cancer	0.000155	0.00291	CcSEcCtD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—esophageal cancer	0.000155	0.00537	CbGpPWpGaD
Topotecan—Anaemia—Capecitabine—esophageal cancer	0.000154	0.0029	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000153	0.00532	CbGpPWpGaD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000153	0.00531	CbGpPWpGaD
Topotecan—Sweating—Methotrexate—esophageal cancer	0.000152	0.00287	CcSEcCtD
Topotecan—Feeling abnormal—Cisplatin—esophageal cancer	0.000152	0.00287	CcSEcCtD
Topotecan—Malaise—Capecitabine—esophageal cancer	0.000151	0.00283	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00015	0.00283	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—esophageal cancer	0.00015	0.00282	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.00015	0.0052	CbGpPWpGaD
Topotecan—Leukopenia—Capecitabine—esophageal cancer	0.000149	0.00281	CcSEcCtD
Topotecan—Body temperature increased—Cisplatin—esophageal cancer	0.000146	0.00275	CcSEcCtD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000146	0.00506	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000146	0.00506	CbGpPWpGaD
Topotecan—Cough—Capecitabine—esophageal cancer	0.000146	0.00274	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—esophageal cancer	0.000144	0.0027	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—esophageal cancer	0.000143	0.00269	CcSEcCtD
Topotecan—Arthralgia—Capecitabine—esophageal cancer	0.000142	0.00267	CcSEcCtD
Topotecan—Chest pain—Capecitabine—esophageal cancer	0.000142	0.00267	CcSEcCtD
Topotecan—Myalgia—Capecitabine—esophageal cancer	0.000142	0.00267	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—esophageal cancer	0.000142	0.00267	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000141	0.00266	CcSEcCtD
Topotecan—Discomfort—Capecitabine—esophageal cancer	0.00014	0.00264	CcSEcCtD
Topotecan—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00014	0.00484	CbGpPWpGaD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—CREBBP—esophageal cancer	0.000139	0.00481	CbGpPWpGaD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000137	0.00474	CbGpPWpGaD
Topotecan—Hypersensitivity—Cisplatin—esophageal cancer	0.000136	0.00256	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000136	0.0047	CbGpPWpGaD
Topotecan—Infection—Capecitabine—esophageal cancer	0.000135	0.00255	CcSEcCtD
Topotecan—Nervous system disorder—Capecitabine—esophageal cancer	0.000134	0.00251	CcSEcCtD
Topotecan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000133	0.00251	CcSEcCtD
Topotecan—Asthenia—Cisplatin—esophageal cancer	0.000133	0.00249	CcSEcCtD
Topotecan—Skin disorder—Capecitabine—esophageal cancer	0.000132	0.00249	CcSEcCtD
Topotecan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000132	0.00248	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000131	0.00455	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00013	0.00451	CbGpPWpGaD
Topotecan—Anorexia—Capecitabine—esophageal cancer	0.00013	0.00244	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—esophageal cancer	0.00013	0.00244	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—esophageal cancer	0.000129	0.00243	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000129	0.00242	CcSEcCtD
Topotecan—Chills—Methotrexate—esophageal cancer	0.000128	0.00241	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.000127	0.00441	CbGpPWpGaD
Topotecan—Diarrhoea—Cisplatin—esophageal cancer	0.000126	0.00238	CcSEcCtD
Topotecan—Alopecia—Methotrexate—esophageal cancer	0.000126	0.00237	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000125	0.00433	CbGpPWpGaD
Topotecan—Malnutrition—Methotrexate—esophageal cancer	0.000124	0.00234	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000124	0.00233	CcSEcCtD
Topotecan—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000123	0.00428	CbGpPWpGaD
Topotecan—Paraesthesia—Capecitabine—esophageal cancer	0.000122	0.0023	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.000122	0.00423	CbGpPWpGaD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—ABCB1—esophageal cancer	0.000122	0.00423	CbGpPWpGaD
Topotecan—Dyspnoea—Capecitabine—esophageal cancer	0.000121	0.00228	CcSEcCtD
Topotecan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00012	0.00417	CbGpPWpGaD
Topotecan—Back pain—Methotrexate—esophageal cancer	0.00012	0.00226	CcSEcCtD
Topotecan—Dyspepsia—Capecitabine—esophageal cancer	0.00012	0.00226	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—EP300—esophageal cancer	0.00012	0.00415	CbGpPWpGaD
Topotecan—Decreased appetite—Capecitabine—esophageal cancer	0.000118	0.00223	CcSEcCtD
Topotecan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000118	0.00221	CcSEcCtD
Topotecan—Vomiting—Cisplatin—esophageal cancer	0.000118	0.00221	CcSEcCtD
Topotecan—Fatigue—Capecitabine—esophageal cancer	0.000117	0.00221	CcSEcCtD
Topotecan—Rash—Cisplatin—esophageal cancer	0.000117	0.00219	CcSEcCtD
Topotecan—Constipation—Capecitabine—esophageal cancer	0.000117	0.00219	CcSEcCtD
Topotecan—Pain—Capecitabine—esophageal cancer	0.000117	0.00219	CcSEcCtD
Topotecan—Dermatitis—Cisplatin—esophageal cancer	0.000116	0.00219	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—esophageal cancer	0.000115	0.00217	CcSEcCtD
Topotecan—Anaemia—Methotrexate—esophageal cancer	0.000115	0.00216	CcSEcCtD
Topotecan—Feeling abnormal—Capecitabine—esophageal cancer	0.000112	0.00211	CcSEcCtD
Topotecan—Malaise—Methotrexate—esophageal cancer	0.000112	0.00211	CcSEcCtD
Topotecan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000111	0.0021	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—esophageal cancer	0.000111	0.00209	CcSEcCtD
Topotecan—Nausea—Cisplatin—esophageal cancer	0.00011	0.00207	CcSEcCtD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000109	0.00379	CbGpPWpGaD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000109	0.00377	CbGpPWpGaD
Topotecan—Cough—Methotrexate—esophageal cancer	0.000108	0.00204	CcSEcCtD
Topotecan—Urticaria—Capecitabine—esophageal cancer	0.000108	0.00204	CcSEcCtD
Topotecan—Abdominal pain—Capecitabine—esophageal cancer	0.000108	0.00203	CcSEcCtD
Topotecan—Body temperature increased—Capecitabine—esophageal cancer	0.000108	0.00203	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000106	0.00369	CbGpPWpGaD
Topotecan—Chest pain—Methotrexate—esophageal cancer	0.000106	0.00199	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—esophageal cancer	0.000106	0.00199	CcSEcCtD
Topotecan—Myalgia—Methotrexate—esophageal cancer	0.000106	0.00199	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000105	0.00198	CcSEcCtD
Topotecan—Discomfort—Methotrexate—esophageal cancer	0.000105	0.00197	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—esophageal cancer	0.000101	0.00191	CcSEcCtD
Topotecan—Infection—Methotrexate—esophageal cancer	0.000101	0.0019	CcSEcCtD
Topotecan—Hypersensitivity—Capecitabine—esophageal cancer	0.0001	0.00189	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	9.98e-05	0.00346	CbGpPWpGaD
Topotecan—Nervous system disorder—Methotrexate—esophageal cancer	9.95e-05	0.00187	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—esophageal cancer	9.93e-05	0.00187	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—esophageal cancer	9.85e-05	0.00185	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—esophageal cancer	9.81e-05	0.00184	CcSEcCtD
Topotecan—Asthenia—Capecitabine—esophageal cancer	9.78e-05	0.00184	CcSEcCtD
Topotecan—Anorexia—Methotrexate—esophageal cancer	9.67e-05	0.00182	CcSEcCtD
Topotecan—Pruritus—Capecitabine—esophageal cancer	9.64e-05	0.00181	CcSEcCtD
Topotecan—ABCG2—lung—esophageal cancer	9.52e-05	0.0315	CbGeAlD
Topotecan—ABCG2—HIF-2-alpha transcription factor network—EP300—esophageal cancer	9.44e-05	0.00327	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	9.42e-05	0.00327	CbGpPWpGaD
Topotecan—Diarrhoea—Capecitabine—esophageal cancer	9.32e-05	0.00175	CcSEcCtD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	9.28e-05	0.00322	CbGpPWpGaD
Topotecan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.24e-05	0.00174	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	9.23e-05	0.0032	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	9.22e-05	0.0032	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	9.15e-05	0.00317	CbGpPWpGaD
Topotecan—Paraesthesia—Methotrexate—esophageal cancer	9.11e-05	0.00171	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	9.08e-05	0.00315	CbGpPWpGaD
Topotecan—Dyspnoea—Methotrexate—esophageal cancer	9.04e-05	0.0017	CcSEcCtD
Topotecan—Dizziness—Capecitabine—esophageal cancer	9.01e-05	0.00169	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—esophageal cancer	8.93e-05	0.00168	CcSEcCtD
Topotecan—TOP1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	8.93e-05	0.0031	CbGpPWpGaD
Topotecan—Decreased appetite—Methotrexate—esophageal cancer	8.82e-05	0.00166	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.76e-05	0.00165	CcSEcCtD
Topotecan—Fatigue—Methotrexate—esophageal cancer	8.75e-05	0.00164	CcSEcCtD
Topotecan—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	8.69e-05	0.00301	CbGpPWpGaD
Topotecan—Pain—Methotrexate—esophageal cancer	8.67e-05	0.00163	CcSEcCtD
Topotecan—Vomiting—Capecitabine—esophageal cancer	8.66e-05	0.00163	CcSEcCtD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	8.64e-05	0.003	CbGpPWpGaD
Topotecan—Rash—Capecitabine—esophageal cancer	8.59e-05	0.00162	CcSEcCtD
Topotecan—Dermatitis—Capecitabine—esophageal cancer	8.58e-05	0.00161	CcSEcCtD
Topotecan—TOP1—Circadian rythm related genes—TP53—esophageal cancer	8.57e-05	0.00297	CbGpPWpGaD
Topotecan—Headache—Capecitabine—esophageal cancer	8.54e-05	0.00161	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—esophageal cancer	8.36e-05	0.00157	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—esophageal cancer	8.3e-05	0.00156	CcSEcCtD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	8.16e-05	0.00283	CbGpPWpGaD
Topotecan—Nausea—Capecitabine—esophageal cancer	8.09e-05	0.00152	CcSEcCtD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	8.09e-05	0.0028	CbGpPWpGaD
Topotecan—Urticaria—Methotrexate—esophageal cancer	8.06e-05	0.00152	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—esophageal cancer	8.02e-05	0.00151	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—esophageal cancer	8.02e-05	0.00151	CcSEcCtD
Topotecan—CYP3A4—digestive system—esophageal cancer	7.94e-05	0.0263	CbGeAlD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	7.52e-05	0.00261	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	7.48e-05	0.00259	CbGpPWpGaD
Topotecan—Hypersensitivity—Methotrexate—esophageal cancer	7.47e-05	0.00141	CcSEcCtD
Topotecan—ABCB1—epithelium—esophageal cancer	7.39e-05	0.0245	CbGeAlD
Topotecan—Asthenia—Methotrexate—esophageal cancer	7.28e-05	0.00137	CcSEcCtD
Topotecan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	7.25e-05	0.00251	CbGpPWpGaD
Topotecan—Pruritus—Methotrexate—esophageal cancer	7.18e-05	0.00135	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—esophageal cancer	6.94e-05	0.00131	CcSEcCtD
Topotecan—ABCG2—Fluoropyrimidine Activity—TP53—esophageal cancer	6.92e-05	0.0024	CbGpPWpGaD
Topotecan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	6.91e-05	0.0024	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	6.87e-05	0.00238	CbGpPWpGaD
Topotecan—Dizziness—Methotrexate—esophageal cancer	6.71e-05	0.00126	CcSEcCtD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	6.61e-05	0.00229	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	6.6e-05	0.00229	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	6.59e-05	0.00228	CbGpPWpGaD
Topotecan—ABCB1—trachea—esophageal cancer	6.53e-05	0.0216	CbGeAlD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	6.52e-05	0.00226	CbGpPWpGaD
Topotecan—ABCG2—lymph node—esophageal cancer	6.51e-05	0.0216	CbGeAlD
Topotecan—Vomiting—Methotrexate—esophageal cancer	6.45e-05	0.00121	CcSEcCtD
Topotecan—Rash—Methotrexate—esophageal cancer	6.4e-05	0.0012	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—esophageal cancer	6.39e-05	0.0012	CcSEcCtD
Topotecan—Headache—Methotrexate—esophageal cancer	6.36e-05	0.0012	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	6.32e-05	0.00219	CbGpPWpGaD
Topotecan—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	6.19e-05	0.00215	CbGpPWpGaD
Topotecan—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	6.14e-05	0.00213	CbGpPWpGaD
Topotecan—Nausea—Methotrexate—esophageal cancer	6.03e-05	0.00113	CcSEcCtD
Topotecan—ABCG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	5.94e-05	0.00206	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	5.81e-05	0.00201	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	5.7e-05	0.00198	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	5.63e-05	0.00195	CbGpPWpGaD
Topotecan—ABCB1—digestive system—esophageal cancer	5.62e-05	0.0186	CbGeAlD
Topotecan—ABCG2—HIF-1-alpha transcription factor network—EP300—esophageal cancer	5.55e-05	0.00193	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	5.4e-05	0.00187	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	5.37e-05	0.00186	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	5.36e-05	0.00186	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	5.33e-05	0.00185	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	5.26e-05	0.00182	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	5.15e-05	0.00178	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	5.15e-05	0.00178	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	5.08e-05	0.00176	CbGpPWpGaD
Topotecan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	5.01e-05	0.00174	CbGpPWpGaD
Topotecan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	4.94e-05	0.00171	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	4.91e-05	0.0017	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	4.9e-05	0.0017	CbGpPWpGaD
Topotecan—ABCB1—lung—esophageal cancer	4.69e-05	0.0155	CbGeAlD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	4.41e-05	0.00153	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	4.32e-05	0.0015	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	4.3e-05	0.00149	CbGpPWpGaD
Topotecan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	4.06e-05	0.00141	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	3.99e-05	0.00138	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	3.95e-05	0.00137	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	3.94e-05	0.00137	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.9e-05	0.00135	CbGpPWpGaD
Topotecan—ABCB1—Allograft Rejection—CASP8—esophageal cancer	3.84e-05	0.00133	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	3.71e-05	0.00129	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	3.66e-05	0.00127	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	3.61e-05	0.00125	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	3.54e-05	0.00123	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC52A3—esophageal cancer	3.48e-05	0.00121	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—BLVRB—esophageal cancer	3.48e-05	0.00121	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	3.44e-05	0.00119	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	3.41e-05	0.00118	CbGpPWpGaD
Topotecan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	3.32e-05	0.00115	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	3.21e-05	0.00111	CbGpPWpGaD
Topotecan—ABCB1—lymph node—esophageal cancer	3.21e-05	0.0106	CbGeAlD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	3.04e-05	0.00106	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	3.03e-05	0.00105	CbGpPWpGaD
Topotecan—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	3e-05	0.00104	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—SLC10A2—esophageal cancer	2.96e-05	0.00103	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CA1—esophageal cancer	2.96e-05	0.00103	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	2.91e-05	0.00101	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	2.9e-05	0.00101	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	2.88e-05	0.000998	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	2.85e-05	0.000987	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	2.82e-05	0.000977	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	2.78e-05	0.000965	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	2.78e-05	0.000965	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CA2—esophageal cancer	2.71e-05	0.000938	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	2.7e-05	0.000935	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	2.67e-05	0.000925	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PLCE1—esophageal cancer	2.52e-05	0.000872	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ADH7—esophageal cancer	2.52e-05	0.000872	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	2.29e-05	0.000795	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	2.26e-05	0.000784	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ADH1B—esophageal cancer	2.21e-05	0.000765	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.16e-05	0.000748	CbGpPWpGaD
Topotecan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	2.16e-05	0.000748	CbGpPWpGaD
Topotecan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	2.13e-05	0.000737	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.11e-05	0.000731	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TYMP—esophageal cancer	2.11e-05	0.000731	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	2.07e-05	0.000718	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP26A1—esophageal cancer	2.05e-05	0.000711	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALOX15—esophageal cancer	2e-05	0.000693	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	1.91e-05	0.000664	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTO1—esophageal cancer	1.91e-05	0.000661	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—TPI1—esophageal cancer	1.91e-05	0.000661	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	1.89e-05	0.000656	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	1.88e-05	0.000653	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC52A3—esophageal cancer	1.88e-05	0.000652	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—BLVRB—esophageal cancer	1.88e-05	0.000652	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALDOB—esophageal cancer	1.83e-05	0.000634	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GAPDH—esophageal cancer	1.76e-05	0.00061	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CRABP1—esophageal cancer	1.74e-05	0.000604	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GNG7—esophageal cancer	1.66e-05	0.000575	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.62e-05	0.000563	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CA1—esophageal cancer	1.6e-05	0.000554	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—SLC10A2—esophageal cancer	1.6e-05	0.000554	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.58e-05	0.000547	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ALDH2—esophageal cancer	1.55e-05	0.000539	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.54e-05	0.000535	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—GSTT1—esophageal cancer	1.48e-05	0.000512	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CA2—esophageal cancer	1.46e-05	0.000507	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP2A6—esophageal cancer	1.46e-05	0.000506	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.39e-05	0.000483	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS1—esophageal cancer	1.39e-05	0.00048	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ENO1—esophageal cancer	1.39e-05	0.00048	CbGpPWpGaD
Topotecan—ABCG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.38e-05	0.00048	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PSME2—esophageal cancer	1.36e-05	0.000473	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PSME1—esophageal cancer	1.36e-05	0.000473	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PLCE1—esophageal cancer	1.36e-05	0.000471	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ADH7—esophageal cancer	1.36e-05	0.000471	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.35e-05	0.000468	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.28e-05	0.000445	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ADH1B—esophageal cancer	1.19e-05	0.000413	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP1B1—esophageal cancer	1.18e-05	0.000408	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.17e-05	0.000404	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.16e-05	0.000402	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.16e-05	0.000402	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TYMP—esophageal cancer	1.14e-05	0.000395	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.12e-05	0.000388	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.11e-05	0.000384	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CYP19A1—esophageal cancer	1.11e-05	0.000384	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.09e-05	0.000379	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALOX15—esophageal cancer	1.08e-05	0.000375	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—TPI1—esophageal cancer	1.03e-05	0.000357	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTO1—esophageal cancer	1.03e-05	0.000357	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—HMOX1—esophageal cancer	1.01e-05	0.00035	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALDOB—esophageal cancer	9.88e-06	0.000343	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.85e-06	0.000342	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CA1—esophageal cancer	9.85e-06	0.000342	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—ABCB1—esophageal cancer	9.7e-06	0.000336	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GAPDH—esophageal cancer	9.51e-06	0.00033	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	9.49e-06	0.000329	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CRABP1—esophageal cancer	9.43e-06	0.000327	CbGpPWpGaD
Topotecan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	9.18e-06	0.000318	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CA2—esophageal cancer	9.01e-06	0.000312	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GNG7—esophageal cancer	8.97e-06	0.000311	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ALDH2—esophageal cancer	8.4e-06	0.000291	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ADH7—esophageal cancer	8.38e-06	0.00029	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PLCE1—esophageal cancer	8.38e-06	0.00029	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—GSTT1—esophageal cancer	7.99e-06	0.000277	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP2A6—esophageal cancer	7.9e-06	0.000274	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS1—esophageal cancer	7.49e-06	0.00026	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—ENO1—esophageal cancer	7.49e-06	0.00026	CbGpPWpGaD
Topotecan—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.48e-06	0.000259	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PSME1—esophageal cancer	7.38e-06	0.000256	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PSME2—esophageal cancer	7.38e-06	0.000256	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ADH1B—esophageal cancer	7.35e-06	0.000255	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TYMP—esophageal cancer	7.02e-06	0.000243	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.83e-06	0.000237	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.66e-06	0.000231	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—CREBBP—esophageal cancer	6.48e-06	0.000225	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP1B1—esophageal cancer	6.37e-06	0.000221	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.35e-06	0.00022	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—TPI1—esophageal cancer	6.35e-06	0.00022	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.09e-06	0.000211	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CYP19A1—esophageal cancer	5.99e-06	0.000208	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.86e-06	0.000203	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.81e-06	0.000201	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—NOS3—esophageal cancer	5.8e-06	0.000201	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GNG7—esophageal cancer	5.52e-06	0.000191	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—HMOX1—esophageal cancer	5.46e-06	0.000189	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PTGS2—esophageal cancer	5.31e-06	0.000184	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.18e-06	0.000179	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.92e-06	0.000171	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.87e-06	0.000169	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ENO1—esophageal cancer	4.61e-06	0.00016	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.61e-06	0.00016	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PSME2—esophageal cancer	4.55e-06	0.000158	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PSME1—esophageal cancer	4.55e-06	0.000158	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—EP300—esophageal cancer	4.41e-06	0.000153	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.92e-06	0.000136	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.69e-06	0.000128	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—CREBBP—esophageal cancer	3.5e-06	0.000121	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.37e-06	0.000117	CbGpPWpGaD
Topotecan—ABCG2—Metabolism—PIK3CA—esophageal cancer	3.27e-06	0.000113	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.23e-06	0.000112	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—NOS3—esophageal cancer	3.14e-06	0.000109	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PTGS2—esophageal cancer	2.87e-06	9.95e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—EP300—esophageal cancer	2.39e-06	8.27e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.16e-06	7.48e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—NOS3—esophageal cancer	1.93e-06	6.7e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.77e-06	6.13e-05	CbGpPWpGaD
Topotecan—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.77e-06	6.12e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—EP300—esophageal cancer	1.47e-06	5.1e-05	CbGpPWpGaD
Topotecan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.09e-06	3.77e-05	CbGpPWpGaD
